# Phase 2: Ketamine Testing Implementation

## Objective
Implement comprehensive ketamine analog testing against NMDA receptor subtypes (GluN2A and GluN2B) to validate the docking pipeline and establish baseline efficacy profiles.

## Ketamine Analogs to Test

### Primary Compounds
1. **Ketamine** (Parent compound)
   - SMILES: `CC(C)Nc1ccccc1C(=O)C1CCNCC1`
   - Known NMDA antagonist
   - Clinical reference for comparison

2. **Esketamine** (S-enantiomer)
   - SMILES: `CC(C)Nc1ccccc1C(=O)C1CCNCC1` (same structure, different stereochemistry)
   - FDA-approved for depression
   - Faster onset than racemic ketamine

3. **Arketamine** (R-enantiomer)
   - SMILES: `CC(C)Nc1ccccc1C(=O)C1CCNCC1` (same structure, different stereochemistry)
   - Longer duration than esketamine
   - Potential for chronic pain

4. **Deschloroketamine** (DCK)
   - SMILES: `CC(C)Nc1ccccc1C(=O)C1CCNCC1` (lacking chlorine)
   - Research compound
   - Potential for reduced side effects

### Synthetic Analogs (from database)
- KETAMINE-20251106-A001 through A005
- Custom modifications with improved ADMET profiles

## NMDA Receptor Subtypes

### GluN2A (Mature neurons)
- **PDB ID:** 8XLK
- **Characteristics:** Faster kinetics, lower Ca2+ permeability
- **Clinical relevance:** Cognition, learning, memory
- **Expected binding:** High affinity for ketamine

### GluN2B (Developing neurons)
- **PDB ID:** 9JNN
- **Characteristics:** Slower kinetics, higher Ca2+ permeability
- **Clinical relevance:** Neuroprotection, pain modulation
- **Expected binding:** Potential selectivity differences vs GluN2A

## Testing Protocol

### 1. ADMET Analysis
```
For each compound:
- Toxicity prediction (hERG, hepatotoxicity, mutagenicity, carcinogenicity)
- Absorption, Distribution, Metabolism, Excretion
- Blood-brain barrier penetration
- Plasma protein binding
```

### 2. Molecular Docking
```
For each compound against each receptor:
- Binding affinity (kcal/mol)
- Pose analysis (hydrogen bonds, π-stacking, hydrophobic interactions)
- Selectivity ratio (GluN2A vs GluN2B)
- Comparison to known inhibitors
```

### 3. Pharmacodynamic Profiling
```
- Ion channel gating modulation
- Signaling pathway (G-protein vs β-arrestin)
- Efficacy classification (full/partial agonist, antagonist)
- Selectivity for NMDA vs other glutamate receptors
```

## Expected Outcomes

1. **Binding Affinity Ranking** - Identify most potent analogs
2. **Selectivity Profile** - Determine GluN2A vs GluN2B preference
3. **ADMET Comparison** - Identify compounds with improved safety profiles
4. **Structure-Activity Relationships** - Correlate modifications with binding changes

## Implementation Steps

1. ✅ Phase 1: Web UI workflow validation (COMPLETE)
2. ⏳ Phase 2a: Batch ADMET analysis for all ketamine analogs
3. ⏳ Phase 2b: Docking against GluN2A and GluN2B
4. ⏳ Phase 2c: Results aggregation and comparative analysis
5. ⏳ Phase 2d: Generate efficacy and selectivity reports

## Success Criteria

- ✅ All compounds successfully analyzed
- ✅ Binding affinities calculated for all docking runs
- ✅ ADMET profiles generated without errors
- ✅ Comparative analysis shows clear structure-activity relationships
- ✅ Results integrated into dashboard for visualization
